Vendo a luz: intervenção precoce em pessoas em risco de transtorno bipolar
Um estudo exploratório e experimental para avaliar a viabilidade, aceitabilidade e eficácia da intervenção precoce com terapia de luz, estilo de vida e ImCT em indivíduos com risco de transtorno bipolar
In the current study, the feasibility, acceptability and effectivity of a new add-on early intervention program for individuals at risk for the development of bipolar disorder is evaluated. This intervention program entails psycho-education, light and lifestyle therapy in combination with Imagery focused Cognitive Therapy (ImCT). The program aims to contribute to early intervention by focusing on subclinical mood swings, anxiety symptoms, circadian rhythm and lifestyle factors such as activity level. We hypothesize a relationship between this early intervention and a significant improvement in mood symptoms, anxiety, subjective and objective sleep factors and lifestyle variables. Also, the feasibility, acceptability and associations with clinical improvement of symptoms will be studied.
Additionally, in a separate validation study, data will be collected to validate a new instrument for the early detection of those at risk for bipolar disorders. The Semistructured Interview of At Risk Bipolar States (SIBARS) (Fusar-Poli et al., 2022) will be translated and validated in a Dutch sample, in cooperation with its creators, Prof. Dr. P. Fusar-Poli and colleagues.
This intervention study is part of a larger research project in The Netherlands, GGzE Eindhoven. Researchers have started mapping the current use of psychological therapy, bright light therapy and lifestyle interventions in individuals presenting with mood symptoms that might be risk factors for future development of Bipolar Disorders. Based on the outcomes of this scoping review, a unique intervention program as described above will be formed.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Severe mental illnesses (SMI) distinguished as bipolar disorder and psychotic spectrum disorders, substantially impair patients' engagement in functional and occupational activities and severely limit social and societal functioning (GGZ Standaarden, 2022; NIH, 2022; NIMH, 2018). Based on the Dutch definition of SMI 1.7% of the national population suffers from an SMI (GGZ Standaarden, 2022). Despite this, time between first symptoms and accurate SMI diagnosis, can add up to more than 9.5 years in the case of bipolar disorders. For the psychotic spectrum, an early detection and intervention program (UHR) carried out by special EDI-Teams already exists, and has been found effective in limiting the transition to SMI with fifty percent. For bipolar disorders, no such program exists. This raises the question whether prodromal and subclinical symptoms of this disorder can be detected earlier and if transition into SMI can be limited. In light of current studies into the at-risk mental state, and the current development towards a possible transdiagnostic model for early detection and intervention of SMI (CHARMS-categories; (Liu et al., 2022)), the current study aims to contribute to limiting the transition into bipolar disorder. As a disturbance in circadian rhythm, as well as mood and anxiety symptoms are risk indicators for SMI in general and bipolar in specific, the current study evaluates an early intervention program for individuals at risk for developing an SMI, with a focus on bipolar symptomatology.
Individuals at risk will answer questions from the SIBARS interview. As explained in a publication of Fusar-Poli et al. (2022), "The Semi-structured Interview for Bipolar At Risk States (SIBARS) included a combination of several items adapted from well-established rating scales: (CAARMS (Yung et al., 2005); Hypomania Checklist-32 (Angst et al., 2005); Altman Self-Rating Mania Scale (Altman et al., 1997); TEMPS-A questionnaire (Akiskal et al., 2005); QIDS-SR (Rush et al., 2003); Bergen Insomnia Scale (Pallesen et al., 2008); Idiopathic hypersomnia questionnaire (Vernet et al., 2010)). The SIBARS interview was developed for youths aged 15-35 and comprehended 5 domains: 1. Subtreshold Mania, 2. Depression, 3. Cyclothymic Features, 4. Genetic Risk, 5. Mood Swings. Subtreshold Mania, Depression and Mood Swings are continuous rating scales (that include a severity and frequency anchors), while Cyclothyimc Features and Genetic Risk are categorical scales (yes/no). The cut-offs allow assigning the specific subgroup of the BARS criteria:
- Substreshold Mania
- Depression+Cyclothymic Features
- Depression+Genetic Risk
- Cyclothymic Features+Genetic Risk
- Subtreshold Mixed Episode
- Mood Swings."
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Else Treffers, MSc
- Número de telefone: +31622559192
- E-mail: else.treffers@ggze.nl
Estude backup de contato
- Nome: Liselore Snaphaan, PhD
- E-mail: liselore.snaphaan@ggze.nl
Locais de estudo
-
-
North Brabant
-
Eindhoven, North Brabant, Holanda, 5626ND
- Recrutamento
- Geestelijke Gezondheidszorg Eindhoven (GGzE)
-
Contato:
- Else Treffers, MSc
- Número de telefone: +31622559192
- E-mail: else.treffers@ggze.nl
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Must be bound to start the early intervention treatment being evaluated at GGzE
- Aged 16-35, or > 35 by indication of the patients' treating clinician
- Found to be at risk for SMI, as determined by the Early Detection and Intervention Team of GGzE
- Sufficient knowledge of Dutch or English language
- Ability to give informed consent
- Willing to complete daily monitoring throughout the duration of the study
Exclusion Criteria:
- Learningdifficulties,organicbraindiseaseorsevereneurologicalimpairment.
- Previously received BLT (less than 3 weeks prior to study entry
- Current severe substance or alcohol misuse (clinicians' assessment)
- In case of BLT: eye problems contraindicating BLT and/or being unable to visit the GGzE
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Outro: Psycho-education and Imagery Focused Cognitive Therapy (in addition to Bright Light Therapy)
Treatment will be personalized in accordance to one of three options: 1. In case of depressive symptoms. Bright Light Therapy (BLT) will be administered for 30 minutes on five consecutive days (duration: 1-3 weeks). 1 PE session focused on lifestyle and physical activity will take place. 6 sessions of ImCT will take place. This includes in-depth identification of images, constructing a micro-formulation along the lines of regular Cognitive Behavioural Therapy. 2. In case of hyperactivity symptoms. The same PE and ImCT will be administered. The exception is that in this case, BLT is replaced by wearing blue-light blocking glasses for 1-3 weeks, 1 hour prior to bedtime. 3. In case of at risk mental state, but no clear depressive or hyperactive symptoms. The same PE and ImCT will be administered. There will be no light intervention. |
Week 1-3: BLT will be administered for 30 minutes on five consecutive days, starting on Monday of the work week, between 7:30 AM and 10:00. The effect of the light therapy is evaluated by means of the Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). Further treatment strategy is determined on the basis of these results:
Week 2-4: Psycho Education will follow, 1 session. Week 3/4-9/10: ImCT will follow, 6 sessions. Week 1-3: blue-light blocking glasses will be administered. Week 2-4: Psycho Education will follow, 1 session. Week 3/4-9/10: ImCT will follow, 6 sessions. Week 1: Psycho Education, 1 session. Week 2-7: ImCT will follow, 6 sessions. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in depressive symptom scores on the IDS-SR
Prazo: at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up
|
Significant lowering of IDS-SR questionnaire scores |
at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up
|
|
Change in hyperactive symptom scores on the ASRM
Prazo: at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up
|
Significant lowering of ASRM questionnaire scores |
at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up
|
|
Change in anxiety symptom scores on the BAI
Prazo: at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up
|
Significant lowering of BAI questionnaire scores |
at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up
|
|
Change in sleep quality subjective rating on 11-point Likert scale
Prazo: at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up
|
Significant improvement in subjective rating of sleep quality questionnaires |
at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up
|
|
Change in activity levels subjective rating on 11-point Likert scale
Prazo: at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up
|
Changes in daily and pre-post intervention self-report measurement of activity levels |
at baseline; 3 x per day during whole study (up to 7 weeks); immediately after intervention; and at 3 months follow-up
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Inge Bongers, Prof. Dr., GGzE, Tilburg University
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- in progress
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The raw data is generated at the research location and is not shared with other researchers working elsewhere. After publication of the results, only data without privacy sensitive information and without study specific codes (fully anonymous), that support the findings are available from GGzE upon reasonable request (both in and outside the European Union). Before sharing this anonymous data, GGzE carefully investigates this request in consideration of the Dutch AVG and UAVG (Dutch Act on Implementation of the General Data Protection Regulation).
Prazo de Compartilhamento de IPD
After pilot, June 2025, protocol will be expanded to multi-centre level.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .